Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Read more about Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 Read more about AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Read more about US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes Read more about Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction Read more about Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
Bayer’s Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Read more about Bayer’s Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes
FARXIGA approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes Read more about FARXIGA approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes
U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Read more about U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Novartis Entresto® granted expanded indication in chronic heart failure by FDA Read more about Novartis Entresto® granted expanded indication in chronic heart failure by FDA
Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat) Read more about Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)
